Rigel Pharmaceuticals Inc (RIGL) Stock Price & Analysis
Rigel Pharmaceuticals Inc (RIGL) rose 0.35% to USD 48.67 as of September 8, 2026 at 09:02 UTC, according to Nexqual real-time market data.
RIGL last closed at USD 48.67; the session ranged USD 48.04–48.87 on volume of 104,968 shares. Market capitalization is —, with a 52-week range of USD 24.95–52.24 (NMS). Source: Nexqual, September 8, 2026 at 09:02 UTC.
Key Statistics (as of September 8, 2026 at 09:02 UTC)
| Price | USD 48.67 |
|---|---|
| Change | ▲ 0.35% (up) |
| Previous Close | USD 48.67 |
| Open | USD 48.67 |
| Day Range | USD 48.04 – 48.87 |
| 52-Week Range | USD 24.95 – 52.24 |
| Volume | 104,968 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (RIGL)
Nexqual's technical model rates RIGL "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 09:02 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.11 (neutral) |
| vs SMA50 | Above (USD 41.86) |
| MACD | 2.25 (positive) |
From Rigel Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- The litigation resulted from submission by Annora of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of TAVALISSE in the US.
- Grifols has launched TAVLESSE in the UK and certain countries in EU including Germany, France, Italy and Spain, and continues a phased rollout across the rest of EU.
Partnerships
- Global Strategic Partnership with Lilly In February 2021, we entered global exclusive license and strategic collaboration with Lilly to develop and commercialize ocadusertib (previously R552), an investigational, potent and selective RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases, and additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases.
- Fostamatinib outside of the US We have a commercialization license agreement with Grifols for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop, fostamatinib in their territory.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VSTM | Verastem, Inc. | USD 8.2 | ▲ 2.24% |
| CRIS | Curis, Inc. | USD 1.35 | ▼ 2.17% |
| LXRX | Lexicon Pharmaceuticals, Inc. | USD 2.24 | ▲ 0% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.96 | ▼ 2.06% |
| VNDA | Vanda Pharmaceuticals Inc. | USD 5.43 | ▼ 1.81% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:02 UTC. This page is informational and not investment advice.